Sec Form 3/A Filing - Simcere Zaiming, Inc. @ NextCure, Inc. - 2025-06-20

FORM 3/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Simcere Zaiming, Inc. 2. Issuer Name and Ticker or Trading Symbol NextCure, Inc. [ NXTC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 20 ACORN PARK DR., 3. Date of Earliest Transaction (MM/DD/YY) 06/20/2025 (Street) CAMBRIDGE, MA02140 4. If Amendment, Date Original Filed (MM/DD/YY) 08/19/2025 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 338,636 I See footnotes ( 1 ) ( 2 ) ( 3 ) ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Simcere Zaiming, Inc. 20 ACORN PARK DR. CAMBRIDGE, MA02140 X Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. BUILDING 23, NO.699-18, XUANWU AVENUE, NANJING NANJING CITY, JIANGSU PROVINCE, F4210000 X Hainan Simcere Zaiming Pharmaceutical Co., Ltd. NO 20, YAOGUYIHENG ROAD, XIUYING DISTRICT HAIKOU CITY, HAINAN PROVINCE, F4570100 X Simcere Pharmaceutical Group Ltd BUILDING 23, NO.699-18, XUANWU AVENUE NANJING CITY, JIANGSU PROVINCE, F4210000 X Ren Jinsheng BUILDING 23, NO.699-18, XUANWU AVENUE NANJING CITY, JIANGSU PROVINCE, F4210000 X Tang Renhong BUILDING 23, NO.699-18, XUANWU AVENUE NANJING CITY, JIANGSU PROVINCE, F4210000 X Signatures Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer 09/29/2025 Signature of Reporting Person Date Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Director and Attorney-in-Fact 09/29/2025 Signature of Reporting Person Date Hainan Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Chief Executive Officer and Chairman of the Board of Directors 09/29/2025 Signature of Reporting Person Date Simcere Pharmaceutical Group Limited By: /s/ Jinsheng Ren Chief Executive Officer and Chairman of the Board of Directors 09/29/2025 Signature of Reporting Person Date Jinsheng Ren By: /s/ Jinsheng Ren 09/29/2025 Signature of Reporting Person Date Renhong Tang By: /s/ Renhong Tang 09/29/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to be indirectly beneficially owned by the other reporting persons (the "Reporting Persons"). ( 2 )Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote. ( 3 )The Reporting Persons disclaim beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. ( 4 )This amendment is being made solely for the purpose of including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons to the Form 3 filed by Simcere Zaiming on 8/19/2025 (the "Original Form"). Although Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong were disclosed in the Original Form, they were unable to be included as reporting persons because they did not have codes for, or lost electronic access to, the EDGAR system at the time. Other than including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons, this form contains no amendment to the Original Form.

Remarks: Exhibit List: Exhibit 24 - Power of Attorney, incorporated by reference to Exhibit 24 to the Schedule 13G filed by Reporting Persons with the Securities and Exchange Commission on August 19, 2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.